Early ixotatug vedotin and bevacizumab data suggest activity in Claudin 6-positive ovarian cancer, but the small uncontrolled study cannot yet separate ADC efficacy from combination effects.
Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.
Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.
Pillar Biosciences launches rapid AML sequencing panel as Creatv Bio liquid biopsy enters colorectal cancer trial. Explore what these tools mean for oncology research.
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
Eli Lilly and Company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational antibody-drug conjugate, sofetabart mipitecan, also known as LY4170156. The designation applies to adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior treatment with bevacizumab and mirvetuximab soravtansine. The novel